In 2019, a research group led by Andrés Ozaita, of the Department of Medicine and Life Sciences at Pompeu Fabra University, described that mice models for Down syndrome have more cannabinoid receptor 1 (CBR1) in some regions of the brain. This anomaly affects the animals’ memory. Six years later, phase 1–2 clinical trials are now underway to test drugs that might correct these alterations in the memory of people living with the syndrome.
This article was originally published on MedicalXpress.com
